Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
Versant Venture Capital VI, L.P. - 07 Jan 2026 SCHEDULE 13D/A Report for Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share (GLUE)
- Filing manager
- Versant Venture Capital VI, L.P.
- Reporting owner
- Versant Venture Capital VI, L.P.
- Beneficially owned shares
- 2,236,708 shares
- Large-stake signal
-
Ownership
3.4%Beneficial ownership of this reported class.
Shares
2,236,708 sharesShares beneficially owned as disclosed.
Event date
07 Jan 2026Date tied to the ownership event or amendment.
Accepted by SEC
09 Jan 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 3.4%
- Symbol
- GLUE
- Shares outstanding
- 65,785,529 shares
- SEC form
- SCHEDULE 13D/A
- Accepted by SEC
- 09 Jan 2026, 16:19:08 UTC
- Event date
- 07 Jan 2026
- Prior SEC filing
- 12 Nov 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
Versant Venture Capital VI, L.P. disclosed 3.4% ownership in Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share (GLUE) on 07 Jan 2026.
Key facts
- Versant Venture Capital VI, L.P. filed SCHEDULE 13D/A for Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share (GLUE).
- Disclosed ownership: 3.4%.
- Date of event: 07 Jan 2026.
Change
- Previous schedule filing date: 12 Nov 2025.
- Current filing was accepted on 09 Jan 2026, 16:19.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (6)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. | 3.4% | 2,236,708 | 2,236,708 | 0 | /s/Max Eisenberg | Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the GP of Versant Ventures VI GP, L.P., the GP of Versant Venture Capital VI, L.P. | 0001687880 |
| Versant Ventures VI GP, L.P. | 3.4% | 2,236,708 | 0 | 2,236,708 | /s/Max Eisenberg | Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the General Partner of Versant Ventures VI GP, L.P. | 0001777654 |
| Versant Ventures VI GP-GP, LLC | 3.4% | 2,236,708 | 0 | 2,236,708 | /s/Max Eisenberg | Max Eisenberg/COO | 0001777652 |
| Versant Vantage I, L.P. | 1.6% | 1,013,361 | 1,013,361 | 0 | /s/Max Eisenberg | Max Eisenberg/COO of Versant Vantage I GP-GP, LLC, the GP of Versant Vantage I GP, L.P., the GP of Versant Vantage I, L.P. | |
| Versant Vantage I GP, L.P. | 1.6% | 1,013,361 | 0 | 1,013,361 | /s/Max Eisenberg | Max Eisenberg/COO of Versant Vantage I GP-GP, LLC, the General Partner of Versant Vantage I GP, L.P. | |
| Versant Vantage I GP-GP, LLC | 1.6% | 1,013,361 | 0 | 1,013,361 | /s/Max Eisenberg | Max Eisenberg/COO |
CIK / CUSIP context first